← All diseases Infectious diseases

Chronic hepatitis B

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest evidence only (82)Meta-analysis (26)Treatment guideline (6)Randomized trial (32)Systematic review (10)Phase 3 study (8)Clinical trial (630)Review article (169)Early study (phase 1 or 2) (25)Description of some patients (97)Laboratory or animal research (16)Commentary or Editorial (50)Retracted publication (2) Studies currently recruiting participants only (31)

Filter

Publications and studies (2005)

• Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference. (2023/11/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference. (2023/11/01) ♡
• Exhaustion of CD8+ T Cells in HBV Infection: Searching for Serological Markers. (2023/11/01) ♡
• An intronic genetic variant of ZHX2 predicts response to pegylated interferon α therapy in HBeAg-positive chronic hepatitis B patients. (2023/10/28) ♡
• Hepatitis B surface antigen reduction is associated with hepatitis B core-specific CD8 (+) T cell quality. (2023/10/18) ♡
• Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients. (2023/10/15) ♡
• The proteasome activator subunit PSME1 promotes HBV replication by inhibiting the degradation of HBV core protein. (2023/10/14) ♡
• Performance of noninvasive fibrosis indices in chronic hepatitis B during pretreatment and post-treatment periods. (2023/10/01) ♡
• Malignant Portal Vein Thrombosis with No Obvious Liver Parenchymal Mass on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. (2023/10/01) ♡
• Uncovering the immune microenvironment and molecular subtypes of hepatitis B-related liver cirrhosis and developing stable a diagnostic differential model by machine learning and artificial neural networks. (2023/09/22) ♡
• [Fuzheng Huayu capsules reducing development of hepatocellular carcinoma in cirrhotic patients with chronic hepatitis B based on the ratio of neutrophils/lymphocytes]. (2023/09/20) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Efficacy of Biejiajian Pill on Intestinal Microbiota in Patients with Hepatitis B Cirrhosis/Liver Fibrosis: A Randomized Double-Blind Controlled Trial. (2023/09/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Changes in the epidemiological pattern of chronic B hepatitis amongst inmates in Catalonia: current prevalence and predictive variables. (2023/09/01) ♡
• Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate. (2023/08/24) ♡
• Autoimmune Hepatitis Induced by Hepatitis Delta Virus: A Conundrum. (2023/08/16) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B. (2023/08/01) ♡
• The hepatitis B virus promotes the progression of non-alcoholic fatty liver disease through incomplete autophagy. (2023/08/01) ♡
• Human immunodeficiency virus coinfection differentially impacts hepatitis B virus viral markers based on hepatitis Be antigen status in patients with suppressed viremia. (2023/08/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. A Review of the Systemic Manifestations of Hepatitis B Virus Infection, Hepatitis D Virus, Hepatocellular Carcinoma, and Emerging Therapies. (2023/07/17) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Randomized Trial of Tenofovir With or Without Peginterferon Alpha Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B. (2023/07/01) ♡
• Hepatitis B RNA and Core-Related Antigen Provide Value Beyond DNA in Evaluating and But Not Surface Antigen Clearance. (2023/07/01) ♡
• Acute Hepatitis B Virus Infection in North American Adults. (2023/07/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Anti-hepatitis B virus activity of food nutrients and potential mechanisms of action. (2023/07/01) ♡
• Impact of the Route and Schedule of Immunization on the Serological and Virological Response of Chronic Hepatitis B Patients Treated with HebernaSvac. (2023/07/01) ♡
• Depression among Patients with Chronic Hepatitis B: A Cross-sectional Study in a Tertiary Hospital of Bangladesh. (2023/07/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. A Narrative Review on the Specific Pattern of HBV Genotype in Bangladesh: Clinical Implications for Management. (2023/07/01) ♡
• RDW Predicts Fibrosis in Patients with Chronic Hepatitis B Having Persistently Normal ALT Levels. (2023/07/01) ♡
• 96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients. (2023/06/28) ♡
• Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Receiving Finite Periods of Antiviral Therapy. (2023/06/25) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. [Clinical efficacy of entecavir combined with Biejiajian pills and its influence on TCM syndrome scores during the treatment of chronic hepatitis B with hepatic fibrosis and blood stasis syndrome]. (2023/06/20) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Progress and Unfinished Business: Hepatitis B in the United States, 1980-2019. (2023/06/09) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Correlates of chronic hepatitis B virus infection in the general adult population of China: Systematic review and meta-analysis. (2023/06/01) ♡
• Antiviral use among hepatitis B infected patients in a low resource setting in Africa: a case study of West Nile, Uganda. (2023/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Sarcopenia in chronic viral hepatitis: From concept to clinical relevance. (2023/05/27) ♡
• Mechanisms of Ganweikang Tablets against Chronic Hepatitis B: A Comprehensive Study of Network Analysis, Molecular Docking, and Chemical Profiling. (2023/05/08) ♡
• An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir. (2023/04/28) ♡
• Efficacy and Economic Evaluation of Nonbiological Artificial Liver Therapy in Acute-on-chronic Hepatitis B Liver Failure. (2023/04/28) ♡
• Reduction in Intrahepatic cccDNA and Integration of HBV into Chronic Hepatitis B Patients with a Functional Cure. (2023/04/28) ♡
• CD55 Variant Associated with Pegylated Interferon α Therapy Response in HBeAg-positive Chronic Hepatitis B Patients. (2023/04/28) ♡
• Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation. (2023/04/21) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Racial Disparities in Treatment Initiation and Outcomes of Chronic Hepatitis B Virus Infection in North America. (2023/04/03) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective. (2023/04/01) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. A critique and systematic review of the clinical utility of hepatitis B core-related antigen. (2023/04/01) ♡
• Discovery of a first-in-class orally available HBV cccDNA inhibitor. (2023/04/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Chinese herbal formula ruangan granule enhances the efficacy of entecavir to reverse advanced liver fibrosis/early cirrhosis in patients with chronic HBV infection: A multicenter, randomized clinical trial. (2023/04/01) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Fuzheng Huayu preparation (/) combined with tenofovir disoproxil fumarate on hepatitis B: a systematic review and Meta-analysis. (2023/04/01) ♡
• Attacking the public health crisis of hepatocellular carcinoma at its roots. (2023/04/01) ♡
• Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™. (2023/04/01) ♡
• Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing? (2023/03/09) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Development and characterization of a chronic hepatitis B murine model with a mutation in the START codon of an HBV polymerase. (2023/03/08) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.